These include massive arborization of dopaminergic fibers towards GDNF injection sites3, loss of immunoreactivity of tyrosine hydroxylase – the key enzyme in dopamine synthesis4, hyperactivity, and loss of body weight6–8, raising the question of whether ectopic GDNF is safe for PD therapy. This evidence concerns the gene GDNF and Parkinson disease.